<?xml version="1.0" encoding="UTF-8"?>
<ref id="B81-pharmaceuticals-13-00096">
 <label>81.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Fang</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Yang</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Ma</surname>
    <given-names>Y.</given-names>
   </name>
   <name>
    <surname>Hong</surname>
    <given-names>S.</given-names>
   </name>
   <name>
    <surname>Lin</surname>
    <given-names>L.</given-names>
   </name>
   <name>
    <surname>He</surname>
    <given-names>X.</given-names>
   </name>
   <name>
    <surname>Xiong</surname>
    <given-names>J.</given-names>
   </name>
   <name>
    <surname>Li</surname>
    <given-names>P.</given-names>
   </name>
   <name>
    <surname>Zhao</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>Huang</surname>
    <given-names>Y.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: Results from two single-arm, phase 1 trials</article-title>
  <source>Lancet Oncol.</source>
  <year>2018</year>
  <volume>19</volume>
  <fpage>1338</fpage>
  <lpage>1350</lpage>
  <pub-id pub-id-type="doi">10.1016/S1470-2045(18)30495-9</pub-id>
  <pub-id pub-id-type="pmid">30213452</pub-id>
 </element-citation>
</ref>
